Endpoints News 生物医药· Elizabeth Cairns·· 2026-09-30AI 评分50
EASD26会议:Lilly的三重激动剂Retatrutide使60%患者体重降至肥胖阈值以下
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
AI 导读
Eli Lilly在EASD26会议上公布数据,其三重激动剂retatrutide帮助同时患有肥胖症和2型糖尿病的患者体重最多减少18.8%。
正文
MILAN — Eli Lilly said Tuesday that its triple agonist retatrutide helped patients with both obesity and type 2 diabetes lose up to 18.8% of their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news